Mohamed Zeinhom Shares The Results of TACTIS Trial
Mohamed Zeinhom, Lecturer of Neurology at Kafr-Elsheikh University, shared on LinkedIn:
”It is my pleasure to share with you the results of our TACTIS trial, where we found that combining cilostazol with aspirin in large-vessel occlusion minor ischemic stroke or TIA was as effective as ticagrelor and aspirin in preventing recurrent stroke, MI, and death due to vascular events, but resulted in significantly lower rates of hemorrhagic complications.”
Read the full article here.
Article: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the TACTIS trial
Authors: Mohamed Ismaiel, Sherihan Rezk Ahmed, Mohamed G. Zeinhom et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 10:59Wolfgang Miesbach: How Clonal Hematopoiesis May Explain Age-Related Mitochondrial Mutations
-
Jun 26, 2026, 10:52Chinua Onyebuchi: The Future of Stroke Care in Africa Lies in Strong Health Systems
-
Jun 26, 2026, 10:35Habtamu Milkias Wolde: New Insights into Stroke and Traumatic Brain Injury from Global Burden of Disease Data
-
Jun 26, 2026, 10:19Rytis Masiliūnas: Atrial Fibrillation and Stroke Care Disparities Across the Baltic Region
-
Jun 26, 2026, 10:11Kayla Kilani: First-Ever CT Perfusion Scan Performed Inside a Mobile Stroke Unit
-
Jun 26, 2026, 07:38Baraa Nassar: High Clinical Suspicion Is Essential for Early Diagnosis of CVST
-
Jun 26, 2026, 07:10Saleh Shamse Basha: Why APTT Alone Can Be Misleading During UFH Monitoring
-
Jun 26, 2026, 06:01Nicolas Hubacz: A Sharper Look at the Brain’s Vascular Landscape
-
Jun 26, 2026, 05:57Ayse Bahar Keleşoğlu Dinçer: New Insights into Antiphospholipid Syndrome Classification and Recurrent Thrombosis Risk